EP1922070A1 - Combinaison de composes convenant au traitement d'affections respiratoires, notamment la broncho-pneumopathie chronique obstructive (bpco) et l'asthme - Google Patents

Combinaison de composes convenant au traitement d'affections respiratoires, notamment la broncho-pneumopathie chronique obstructive (bpco) et l'asthme

Info

Publication number
EP1922070A1
EP1922070A1 EP06769627A EP06769627A EP1922070A1 EP 1922070 A1 EP1922070 A1 EP 1922070A1 EP 06769627 A EP06769627 A EP 06769627A EP 06769627 A EP06769627 A EP 06769627A EP 1922070 A1 EP1922070 A1 EP 1922070A1
Authority
EP
European Patent Office
Prior art keywords
active ingredient
amino
chlorobenzyl
oxy
piperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06769627A
Other languages
German (de)
English (en)
Inventor
Tomas Eriksson
Johan Hansson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of EP1922070A1 publication Critical patent/EP1922070A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • COPD chronic obstructive pulmonary disease
  • the present invention relates to combinations of pharmaceutically active substances for use in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (COPD) and asthma.
  • COPD chronic obstructive pulmonary disease
  • Respiratory diseases include Acute Lung Injury, Acute Respiratory Distress Syndrome (ARDS), occupational lung disease, lung cancer, tuberculosis, fibrosis, pneumoconiosis, pneumonia, emphysema, Chronic Obstructive Pulmonary Disease (COPD) and asthma.
  • ARDS Acute Respiratory Distress Syndrome
  • COPD Chronic Obstructive Pulmonary Disease
  • Asthma is generally defined as an inflammatory disorder of the airways with clinical symptoms arising from intermittent airflow obstruction. It is characterised clinically by paroxysms of wheezing, dyspnea and cough. It is a chronic disabling disorder that appears to be increasing in prevalence and severity. It is estimated that 15% of children and 5% of adults in the population of developed countries suffer from asthma. Therapy should therefore be aimed at controlling symptoms so that normal life is possible and at the same time provide basis for treating the underlying inflammation.
  • COPD is a term which refers to a large group of lung diseases which can interfere with normal breathing.
  • Current clinical guidelines define COPD as a disease state characterized by airflow limitation that is not fully reversible.
  • the airflow limitation is usually both progressive and associated with an abnormal inflammatory response of the lungs to noxious particles and gases.
  • the most important contributory source of such particles and gases is tobacco smoke.
  • COPD patients have a variety of symptoms, including cough, shortness of breath, and excessive production of sputum; such symptoms arise from dysfunction of a number of cellular compartments, including neutrophils, macrophages, and epithelial cells.
  • the two most important conditions covered by COPD are chronic bronchitis and emphysema.
  • Chronic bronchitis is a long-standing inflammation of the bronchi which causes increased production of mucous and other changes. The patients' symptoms are cough and expectoration of sputum. Chronic bronchitis can lead to more frequent and severe respiratory infections, narrowing and plugging of the bronchi, difficult breathing and disability.
  • Emphysema is a chronic lung disease which affects the alveoli and/or the ends of the smallest bronchi.
  • the lung loses its elasticity and therefore these areas of the lungs become enlarged. These enlarged areas trap stale air and do not effectively exchange it with fresh air. This results in difficult breathing and may result in insufficient oxygen being delivered to the blood.
  • the predominant symptom in patients with emphysema is shortness of breath.
  • Therapeutic agents used in the treatment of respiratory diseases include ⁇ 2 -agonists. These agents (also known as beta2 ( ⁇ 2 ) adrenoreceptor agonists) may be used to alleviate symptoms of respiratory diseases by relaxing the bronchial smooth muscles, reducing airway obstruction, reducing lung hyperinflation and decreasing shortness of breath.
  • ⁇ 2 -agonists also known as beta2 ( ⁇ 2 ) adrenoreceptor agonists
  • WO01/98273 and WO03/051839 describe compounds having activity as pharmaceuticals, in particular as modulators of chemokine receptor (especially MIP- l ⁇ . chemokine receptor), salts thereof and pharmaceutical formulations, and their potential use in treating various diseases.
  • the MEP-l ⁇ chemokine receptor CCRl (chemokine receptor 1) is highly expressed in tissues affected in different autoimmune, inflammatory, proliferative, hyperproliferative and immunologically mediated diseases e.g. asthma and chronic obstructive pulmonary disease.
  • inflammatory cells e.g. neutrophils and monocytes/macrophages
  • a pharmaceutical product comprising, in combination,
  • n 0, 1 or 2; each R independently represents halogen or cyano;
  • R represents a hydrogen atom or methyl
  • R represents the group Ci-C 4 alkyl
  • R represents hydrogen or halogen; or a pharmaceutically acceptable salt thereof; and (b) a second active ingredient which is a ⁇ 2 -agonist.
  • the pharmaceutical product of the present invention may, for example, be a pharmaceutical composition comprising the first and second active ingredients in admixture.
  • the pharmaceutical product may, for example, be a kit comprising a preparation of the first active ingredient and a preparation of the second active ingredient and, optionally, instructions for the simultaneous, sequential or separate administration of the preparations to a patient in need thereof.
  • an alkyl substituent group or an alkyl moiety in a substituent group may be linear or branched.
  • the integer m is preferably 1 or 2.
  • Each R independently represents halogen (e.g. chlorine, fluorine, bromine or iodine) or cyano.
  • m is 1 and R represents a halogen atom, particularly a chlorine atom.
  • m is 1 and R represents a halogen atom (e.g. chlorine) in the 4-position of the benzene ring relative to the carbon atom to which the CH2 linking group is attached. 2 2
  • R represents a hydrogen atom or methyl. In one embodiment of the present invention, R represents methyl.
  • R represents the group C4-C4 alkyl (e.g. methyl, ethyl, n-propyl, isopropyl, n-butyl,
  • R is methyl or ethyl, particularly methyl.
  • 4 R represents hydrogen or halogen (e.g. fluorine, chlorine, bromine or iodine).
  • halogen e.g. fluorine, chlorine, bromine or iodine
  • R represents hydrogen or chlorine.
  • the compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses the use of all geometric and optical isomers of the compounds of formula (I) and mixtures thereof including racemates. The use of tautomers and mixtures thereof also form an aspect of the present invention.
  • Preferred optical isomers are the (S)-enantiomers (i.e. compounds with the S configuration at the stereocentre with R 2 and OH attached).
  • the compounds of formula (I) according to the present invention may be synthesised using the procedures set out in WO01/98273 and WO03/051839.
  • the compounds of formulas (I) may be used in the form of a pharmaceutically acceptable salt, preferably an acid addition salt such as a hydrochloride, hydrobromide, phosphate, sulfphate, acetate, ascorbate, benzoate, fumarate, hemifumarate, furoate, succinate, maleate, tartrate, citrate, oxalate, xinafoate, methanesulphonate orp-toluenesulphonate.
  • a pharmaceutically acceptable salt also includes internal salt (zwitterionic) forms. Any reference to compounds of formula (I) or salts thereof also encompasses solvates of such compounds and salts thereof (e.g. hydrates).
  • the compound of formula (I) is selected from
  • the compound of formula (I) is a salt of N- ⁇ 2-[((2S)-3- ⁇ [l-(4-chlorobenzyl)piperidin-4-yl]amino ⁇ -2-hydroxy-2-methylpropyl)oxy]-4- hy droxyphenyl ⁇ acetamide, for example hydrochloride, hydrobromide, phosphate, sulfphate, acetate, ascorbate, benzoate, fumarate, hemifumarate, furoate, succinate, maleate, tartrate, citrate, oxalate, xinafoate, methanesulphonate or p-toluenesulphonate salt.
  • Salts with particularly good properties are the benzoate, fumarate, or hemifumarate salts of N- ⁇ 2-[((25)-3- ⁇ [l-(4- chlorobenzyl)piperidin-4-yl] amino ⁇ -2-hydroxy-2-methylpropyl)oxy] -A- hy droxyphenyl ⁇ acetamide, including any forms of the salts referred to in the Examples.
  • the compound of formula (I) or salt thereof has crystalline properties and is e.g. at least 50% crystalline, at least 60% crystalline, at least 70% crystalline or at least 80% crystalline. Crystallinity can be estimated by conventional X-ray diffractometry techniques.
  • the compound of formula (I) or salt thereof is from 50%, 60%, 70%, 80% or 90% to 95%, 96%, 97%, 98%, 99% or 100% crystalline.
  • the compound of formula (I) is a hemifumarate salt of N- ⁇ 2- [((2S)-3- ⁇ [ 1 -(4-chlorobenzyl)piperidin-4-yl] amino ⁇ -2-hydroxy-2-methylpropyl)oxy] - 4-hydroxyphenyl ⁇ acetamide which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2 ⁇ ):
  • the compound of formula (I) is a furoate salt of N- ⁇ 2- [((2S)-3 - ⁇ [ 1 -(4-chlorobenzyl)piperidin-4-yl] amino ⁇ -2-hydroxy-2-methylpropyl)oxy]- 4-hydroxyphenyl ⁇ acetamide which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2 ⁇ ): (1) 6.3, 11.0 and 12.7, or
  • the compound of formula (I) is a furoate salt of N- ⁇ 2- [((2S)-3- ⁇ [ l-(4-chlorobenzyl)piperidin-4-yl] amino ⁇ -2-hydroxy-2-methylpropyl)oxy] - I 0 4-hydroxyphenyl ⁇ acetamide which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2 ⁇ ):
  • the compound of formula (I) is a benzoate salt of N- ⁇ 2- [((25)-3- ⁇ [ l-(4-chlorobenzyl)piperidin-4-yl] amino ⁇ -2-hydroxy-2-methylpropyl)oxy] - 4-hydroxyphenyl ⁇ acetamide which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2 ⁇ ):
  • the compound of formula (I) is a benzoate salt of N- ⁇ 2-[((2S)-3- ⁇ [l-(4-chlorobenzyl)piperidin-4-yl]amino ⁇ -2-hydroxy-2-methylpropyl)oxy]- 4-hydroxyphenyl ⁇ acetamide which exhibits at least the following characteristic X-ray powder diffraction peaks (expressed in degrees 2 ⁇ ):
  • the compound of formula (I) is the furoate or benzoate salt of N- ⁇ 5-Chloro-2-[((25)-3- ⁇ [l-(4-chlorobenzyl)piperidin-4-yl]amino ⁇ -2-hydroxy-2- methylpropyl)oxy] -4-hy droxyphenyl ⁇ acetamide.
  • the second active ingredient in the combination of the present invention is a ⁇ 2 -agonist.
  • the ⁇ 2 -agonist of the present invention may be any compound or substance capable of stimulating the ⁇ 2 -receptor and acting as a bronchodilator.
  • Examples of ⁇ 2 -agonists that may be used in the present invention include bambuterol, bitolterol, carbuterol, indacaterol, clenbuterol, fenoterol, formoterol, hexoprenaline, ibuterol, pirbuterol, procaterol, reproterol, salmeterol, sulphonterol, terbutaline, tolubuterol, TA 2005 (chemically identified as 2(1H)-Quinolone, 8-hydroxy-5-[l-hydroxy-2-[[2-(4-methoxy-phenyl)-l- methylethyl]-amino]ethyl]-monohydrochloride, [R-
  • the ⁇ 2 -agonist of the invention is a long acting ⁇ 2 -agonist, i.e. a ⁇ 2 -agonist with activity that persists for more than 12 hours.
  • long acting ⁇ 2 -agonists include formoterol, bambuterol and salmeterol.
  • any reference to a ⁇ 2 - agonist includes active salts, solvates or derivatives that may be formed from said ⁇ 2 - agonist and any enantiomers and mixtures thereof, including racemates.
  • Examples of possible salts or derivatives of ⁇ 2 -agonists are acid addition salts such as the salts of hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, acetic acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid, 1- hydroxy-2-naphthalenecarboxylic acid, maleic acid, and pharmaceutically acceptable esters (e.g. C 1 -Ce alkyl esters).
  • the ⁇ 2 -agonists may also be in the form of a solvate, e.g. a hydrate.
  • the ⁇ 2 -agonist is formoterol.
  • the chemical name for formoterol is N-[2-hydroxy-5-[(l)-l-hydroxy-2-[[(l)-2-(4-methoxyphenyl)-l- methylethyl]amino]ethyl]phenyl]-formamide.
  • the preparation of formoterol is described, for example, in WO 92/05147.
  • the term formoterol is intended to include all pharmaceutically acceptable salts thereof.
  • the ⁇ 2 -agonist is formoterol fumarate, for example formoterol fumarate dihydrate.
  • the invention encompasses the use of all optical isomers of formoterol and mixtures thereof including racemates.
  • formoterol encompasses N-[2-hydroxy-5-[(l/?)-l-hydroxy-2-[[(lR)-2-(4- methoxyphenyl)-l-methylethyl]amino]ethyl]phenyl]-formamide, N-[2-hydroxy-5-[(15)-l- hydroxy-2- [[( lS)-2-(4-methoxyphenyl)-l -methylethyl] amino] ethyl]phenyl] -f ormamide or a mixture of such enantiomers, including a racemate.
  • the ⁇ 2 -agonist is indacaterol.
  • indacaterol is intended to include all pharmaceutically acceptable salts thereof, including for example, indacaterol maleate and indacaterol hydrochloride.
  • the compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof (first active ingredient) and ⁇ 2 -agonist (second active ingredient) of the present invention may be administered simultaneously, sequentially or separately to treat respiratory diseases.
  • sequential it is meant that the active ingredients are administered, in any order, one immediately after the other. They still have the desired effect if they are administered separately, but when administered in this manner they are generally administerted less than 4 hours apart, more conveniently less than two hours apart, more conveniently less than 30 minutes apart and most conveniently less than 10 minutes apart.
  • the active ingredients of the present invention may be administered by oral or parenteral (e.g. intravenous, subcutaneous, intramuscular or intraarticular) administration using conventional systemic dosage forms, such as tablets, capsules, pills, powders, aqueous or oily solutions or suspensions, emulsions and sterile injectable aqueous or oily solutions or suspensions.
  • the active ingredients may also be administered topically (to the lung and/or airways) in the form of solutions, suspensions, aerosols and dry powder formulations.
  • These dosage forms will usually include one or more pharmaceutically acceptable ingredients which may be selected, for example, from adjuvants, carriers, binders, lubricants, diluents, stabilising agents, buffering agents, emulsifying agents, viscosity- regulating agents, surfactants, preservatives, flavourings and colorants.
  • pharmaceutically acceptable ingredients may be selected, for example, from adjuvants, carriers, binders, lubricants, diluents, stabilising agents, buffering agents, emulsifying agents, viscosity- regulating agents, surfactants, preservatives, flavourings and colorants.
  • the most appropriate method of administering the active ingredients is dependent on a number of factors.
  • the active ingredients are administered via separate pharmaceutical preparations.
  • the present invention provides a kit comprising a preparation of a first active ingredient which is a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a preparation of a second active ingredient which is a ⁇ 2 -agonist, and optionally instructions for the simultaneous, sequential or separate administration of the preparations to a patient in need thereof.
  • the active ingredients may be administered via a single pharmaceutical composition. Therefore, the present invention further provides a pharmaceutical composition comprising, in admixture, a first active ingredient which is compound of formula (I) or pharmaceutically acceptable salt thereof, and a second active ingredient which is ⁇ 2 -agonist.
  • the present invention also provides a process for the preparation of a pharmaceutical composition which comprises mixing the first active ingredient with the second active ingredient.
  • compositions of the present invention may be prepared by mixing the first active ingredient and the second active ingredient with a pharmaceutically acceptable adjuvant, diluent or carrier. Therefore, in a further aspect of the present invention there is provided a process for the preparation of a pharmaceutical composition, which comprises mixing a compound of formula (I) or pharmaceutically acceptable salt thereof, with a ⁇ 2 - agonist and a pharmaceutically acceptable adjuvant, diluent or carrier. It will be understood that the therapeutic dose of each active ingredient administered in accordance with the present invention will vary depending upon the particular active ingredient employed, the mode by which the active ingredient is to be administered, and the condition or disorder to be treated.
  • the first, second (and when present, the third) active ingredients of the present invention are each administered by inhalation.
  • the active ingredients are inhaled simultaneously, sequentially or separately.
  • the amount of the active ingredients used relate to inhaled unit doses unless explicitly defined differently.
  • the dose of the first active ingredient (compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof), will generally be in the range of from 0.1 ⁇ g to 10000 ⁇ g, 0.1 to 5000 ⁇ g, 0.1 to 1000 ⁇ g, 0.1 to 500 ⁇ g, 0.1 to 200 ⁇ g, 0.1 to 200 ⁇ g, 0.1 to 100 ⁇ g, 0.1 to 50 ⁇ g, 5 ⁇ g to 5000 ⁇ g, 5 to 1000 ⁇ g, 5 to 500 ⁇ g, 5 to 200 ⁇ g, 5 to 100 ⁇ g, 5 to 50 ⁇ g, 10 to 5000 ⁇ g, 10 to 1000 ⁇ g, 10 to 500 ⁇ g, 10 to 200 ⁇ g, 10 to 100 ⁇ g, 10 to 50 ⁇ g, 20 to 5000 ⁇ g, 20 to 1000 ⁇ g, 20 to 500 ⁇ g, 20 to 200 ⁇ g, 20 to 100 ⁇ g, 20 to 50 ⁇ g, 50 to 5000 ⁇ g, 50 to 1000 ⁇ g, 50 to
  • the dose of the second active ingredient may conveniently be administered by inhalation at a dose generally in the range of from 0.1 to 100 ⁇ g, 0.1 to 50 ⁇ g, 0.1 to 40 ⁇ g, 0.1 to 30 ⁇ g, 0.1 to 20 ⁇ g, 0.1 to 10 ⁇ g, 5 to 100 ⁇ g, 5 to 50 ⁇ g, 5 to 40 ⁇ g, 5 to 30 ⁇ g, 5 to 20 ⁇ g, 5 to 10 ⁇ g, 10 to 100 ⁇ g, 10 to 50 ⁇ g, 10 to 40 ⁇ g, 10 to 30 ⁇ g, or 10 to 20 ⁇ g.
  • the dose of the third active ingredient is in the range 1 to 30 ⁇ g.
  • the doses of the first and second active ingredients will generally be administered from 1 to 4 times a day, conveniently once or twice a day, and most conveniently once a day.
  • the present invention provides a pharmaceutical product comprising, in combination, a first active ingredient which is a compound of formula (I) or a pharmaceutically acceptable salt thereof, and a second active ingredient which is a ⁇ 2 - agonist, wherein each active ingredient is formulated for inhaled administration.
  • the active ingredients are conveniently administered via inhalation (e.g. topically to the lung and/or airways) in the form of solutions, suspensions, aerosols or dry powder formulations. Administration may be by inhalation orally or intranasally.
  • the active ingredients are preferably adapted to be administered, either together or individually, from a dry powder inhaler, pressurised metered dose inhaler, or a nebuliser.
  • the active ingredients may be used in admixture with one or more pharmaceutically acceptable additives, diluents or carriers.
  • suitable diluents or carriers include lactose (e.g. the monohydrate), dextran, mannitrol or glucose.
  • Metered dose inhaler devices may be used to administer the active ingredients, dispersed in a suitable propellant and with or without additional excipients such as ethanol, a surfactants, a lubricant, an anti-oxidant or a stabilising agent.
  • Suitable propellants include hydrocarbon, chlorofluorocarbon and hydrofluoroalkane (e.g. heptafluoroalkane) propellants, or mixtures of any such propellants.
  • Preferred propellants are Pl 34a and P227, each of which may be used alone or in combination with other propellants and/or surfactant and/or other excipients.
  • Nebulised aqueous suspensions or, preferably, solutions may also be employed, with or without a suitable pH and/or tonicity adjustment, either as a unit-dose or multi-dose formulations.
  • Dry powder inhalers may be used to administer the active ingredients, alone or in combination with a pharmaceutically acceptable carrier, in the later case either as a finely divided powder or as an ordered mixture.
  • the dry powder inhaler may be single dose or multi-dose and may utilise a dry powder or a powder-containing capsule.
  • the active ingredients When the active ingredients are adapted to be administered, either together or individually, via a nebuliser they may be in the form of a nebulised aqueous suspension or solution, with or without a suitable pH or tonicity adjustment, either as a single dose or multidose device.
  • Metered dose inhaler, nebuliser and dry powder inhaler devices are well known and a variety of such devices are available.
  • the compound of formula (I) or pharmaceutically acceptable salt thereof may be administered orally and the other active ingredient(s) administered by inhalation.
  • the present invention further provides a pharmaceutical product, kit or pharmaceutical composition according to the invention for simultaneous, sequential or separate use in therapy.
  • the present invention further provides the use of a pharmaceutical product, kit or pharmaceutical composition according to the invention in the manufacture of a medicament for the treatment of a respiratory disease, in particular chronic obstructive pulmonary disease or asthma.
  • the present invention still further provides a method of treating a respiratory disease which comprises simultaneously, sequentially or separately administering: (a) a (therapeutically effective) dose of a first active ingredient which is a compound of formula (I) or a pharmaceutically acceptable salt thereof; and
  • the term “therapy” also includes “prophylaxis” unless there are specific indications to the contrary.
  • the terms “therapeutic” and “therapeutically” should be construed accordingly. Prophylaxis is expected to be particularly relevant to the treatment of persons who have suffered a previous episode of, or are otherwise considered to be at increased risk of, the condition or disorder in question. Persons at risk of developing a particular condition or disorder generally include those having a family history of the condition or disorder, or those who have been identified by genetic testing or screening to be particularly susceptible to developing the condition or disorder.
  • the pharmaceutical product, kit or composition of the present may optionally comprise a third active ingredient which third active ingredient is a substance suitable for use in the treatment of respiratory diseases.
  • a pharmaceutical product, kit or composition according to the present invention that does not include a glucocorticosteroid as an active ingredient.
  • the hemi-fumarate salt exhibits at least the following characteristic X-ray powder diffraction (XRPD) peaks (expressed in degrees 2 ⁇ ) (the margin of error being consistent with the United States Pharmacopeia general chapter on X-ray diffraction (USP941) - see the United States Pharmacopeia Convention. X-Ray Diffraction, General Test ⁇ 941>. United States Pharmacopeia, 25th ed. Rockville, MD: United States Pharmacopeial Convention; 2002:2088-2089):
  • the precipitate obtained was washed with ethyl acetate (3 x 50 ml) and dried in vacuo at 60 0 C overnight to give the titled salt as an off-white solid (4.41 g, 87%).
  • the salt contained traces of ethyl acetate.
  • the benzoate Form A salt exhibits at least the following characteristic X-ray powder diffraction (XRPD) peaks (expressed in degrees 2 ⁇ ) (the margin of error being consistent with the United States Pharmacopeia general chapter on X-ray diffraction (USP941) - see the United States Pharmacopeia Convention. X-Ray Diffraction, General Test ⁇ 941>. United States Pharmacopeia, 25th ed. Rockville, MD: United States Pharmacopeial Convention; 2002:2088-2089):
  • Form B salt described in (a) above was also prepared by dissolving, in a vial, 20%w of a sample of the benzoate salt prepared by the method of Example l(b) (Form A) in a solvent such as methanol (>20 mg/ml), ethanol (>20 mg/ml), n-propanol (>20 mg/ml), isopropanol (8.5 mg/ml) or acetone (9.6 mg/ml).
  • the figures in brackets indicate the estimated solubility of the salt in these solvents.
  • the vial was then sealed and the suspension was homogenised at ambient temperature (2O 0 C) using a magnet. Stirring and temperature were maintained for a period of at least 7 days after which time a sample of the material obtained was dried and tested by XRPD. XRPD confirmed that there had been complete transformation of Form A to Form B.
  • Form B salt described in (a) above was also prepared by dissolving benzoate salt prepared by the method of Example l(b) (Form A) (22.Og, 37.7mmol) and benzoic acid (0.46 g, 3.8 mmol) in hot 2-propanol (190 ml) in a round-bottomed flask to give a reddish solution.
  • the flask was rotated using a Rotavapor device on a waterbath at 40 0 C until the solution had cooled down to 40 °C, whereupon it was seeded with some crystals of the Form B salt.
  • the waterbath was allowed to cool down slowly to ambient temperature overnight while the flask was rotating and the mixture was seeded occasionally with some crystals of the Form B salt.
  • a pink precipitate which formed was isolated by suction, washed with 2-propanol (2 x 50 ml) and dried in vacuo at 100 0 C for 20 hours to give the titled salt (as confirmed by XRPD) as a pale pink solid (18.5 g, 84%).
  • the salt contained traces of 2-propanol.
  • the stoichiometry, base to acid, of 1:1 was confirmed by NMR.
  • the benzoate Form B salt exhibits at least the following characteristic X-ray powder diffraction (XRPD) peaks (expressed in degrees 2 ⁇ ) (the margin of error being consistent with the United States Pharmacopeia general chapter on X-ray diffraction (USP941) - see the United States Pharmacopeia Convention.
  • XRPD X-ray powder diffraction
  • USP941 X-ray powder diffraction
  • the resulting mixture was stirred for 3 days and a precipitate that formed was isolated, washed with diethylether and dried in vacuo to give an off-white solid (38 mg).
  • the solid contained the titled salt as a crystalline material together with some amorphous salt.
  • the titled salt contained trace amounts of diethylether.
  • the stoichiometry, base to acid, of 1: 1 was confirmed by ⁇ MR.
  • the furoate Form A salt exhibits at least the following characteristic X-ray powder diffraction (XRPD) peaks (expressed in degrees 2 ⁇ ) (the margin of error being consistent with the United States Pharmacopeia general chapter on X-ray diffraction (USP941) - see the United States Pharmacopeia Convention.
  • United States Pharmacopeia, 25th ed. Rockville, MD United States Pharmacopeial Convention; 2002:2088-2089
  • Form B was prepared by dissolving, in a vial, 20%w of a sample of the furoate salt prepared by the method of Example l(b) (Form A) in a solvent such as ethanol (16 mg/ml) or 2-butanol (8 mg/ml). The figures in brackets indicate the estimated solubility of the salt in these solvents.
  • the vial was then sealed and the suspension was homogenised at ambient temperature (20 0 C) using a magnet. Stirring and temperature were maintained for a period of at least 7 days after which time a sample of the material obtained was dried and tested by XRPD. XRPD confirmed that there had been complete transformation of Form A to Form B.
  • the furoate Form B salt exhibits at least the following characteristic X-ray powder diffraction (XRPD) peaks (expressed in degrees 2 ⁇ ) (the margin of error being consistent with the United States Pharmacopeia general chapter on X-ray diffraction (USP941) - see the United States Pharmacopeia Convention. X-Ray Diffraction, General Test ⁇ 941>. United States Pharmacopeia, 25th ed. Rockville, MD: United States Pharmacopeial Convention; 2002:2088-2089):
  • the column was first washed with methanol (3 x 10 mL) and subsequently with a mixture of ammonia/methanol (1/20, 3 x 10 mL).
  • the basic layers were pooled and the solvent removed in vacuo, providing N- ⁇ 5-chloro-2-[((2S)-3- ⁇ [l-(4- chlorobenzyl)piperidin-4-yl]amino ⁇ -2-hydroxypropyl)oxy]-4-methoxyphenyl ⁇ propaneamide as a light brown oil (100 mg, 86%), which was redissolved in dichlormethane (4 mL).
  • the solution was cooled to 0 0 C and IM BBr 3 in dichloromethane (1 mL) added dropwise.
  • HEK293 cells from ECACC, stably expressing recombinant human CCRl (HEK-CCRl) were used to prepare cell membranes containing CCRl.
  • the membranes were stored at -70 0 C.
  • the concentration of membranes of each batch was adjusted to 10% specific binding of 33 pM [ 125 I] MIP-Ia.
  • NSB average cpm in the wells with membranes and MIP- let and [ 125 I] MIP- l ⁇ (nonspecific binding) cpm;
  • BO average cpm in wells with membranes and assay buffer and [ 125 I] MIP- loc (maximum binding).
  • the molar concentration of compound producing 50% displacement (IC 50 ) was derived using the Excel-based program XLfit (version 2.0.9) to fit data to a 4-parameter logistics function.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La présente invention concerne des compositions pharmaceutiques à base de ß2-agoniste, et un composé représenté par la formule (I) dans laquelle m, R1, R2, R3, et R4 sont tels que définis dans la spécification. L'invention concerne également leur utilisation thérapeutique.
EP06769627A 2005-08-26 2006-08-24 Combinaison de composes convenant au traitement d'affections respiratoires, notamment la broncho-pneumopathie chronique obstructive (bpco) et l'asthme Withdrawn EP1922070A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE0501895 2005-08-26
SE0601221 2006-06-01
PCT/SE2006/000971 WO2007024183A1 (fr) 2005-08-26 2006-08-24 Combinaison de composes convenant au traitement d'affections respiratoires, notamment la broncho-pneumopathie chronique obstructive (bpco) et l'asthme

Publications (1)

Publication Number Publication Date
EP1922070A1 true EP1922070A1 (fr) 2008-05-21

Family

ID=37771857

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06769627A Withdrawn EP1922070A1 (fr) 2005-08-26 2006-08-24 Combinaison de composes convenant au traitement d'affections respiratoires, notamment la broncho-pneumopathie chronique obstructive (bpco) et l'asthme

Country Status (12)

Country Link
US (1) US20090298875A1 (fr)
EP (1) EP1922070A1 (fr)
JP (1) JP2009506029A (fr)
KR (1) KR20080038178A (fr)
AU (1) AU2006282122A1 (fr)
BR (1) BRPI0615064A2 (fr)
CA (1) CA2620281A1 (fr)
IL (1) IL189182A0 (fr)
MX (1) MX2008002320A (fr)
NO (1) NO20081483L (fr)
RU (1) RU2008108176A (fr)
WO (1) WO2007024183A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200738634A (en) * 2005-08-02 2007-10-16 Astrazeneca Ab New salt
WO2008103125A1 (fr) * 2007-02-23 2008-08-28 Astrazeneca Ab Nouvelle combinaison de composés utilisés dans le traitement des maladies des voies aériennes, en particulier la bronchopneumopathie chronique obstructive (copd) et l'asthme
US20110124613A1 (en) * 2007-02-23 2011-05-26 Tomas Eriksson Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma
PT2229148E (pt) * 2007-12-13 2014-05-26 Novartis Ag Processo para preparação de uma substância farmacológica particulada e substancialmente cristalina

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994974A (en) * 1972-02-05 1976-11-30 Yamanouchi Pharmaceutical Co., Ltd. α-Aminomethylbenzyl alcohol derivatives
GB8334494D0 (en) * 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
WO2001098270A2 (fr) * 2000-06-21 2001-12-27 Bristol-Myers Squibb Pharma Company N-ureidoalkyl-piperidines utiles comme modulateurs de l'activite du recepteur de chimiokine
US7045658B2 (en) * 2001-03-22 2006-05-16 Glaxo Group Limited Formailide derivatives as beta2-adrenoreceptor agonists
SE0104251D0 (sv) * 2001-12-14 2001-12-14 Astrazeneca Ab Novel compounds
GB0207436D0 (en) * 2002-03-28 2002-05-08 Glaxo Group Ltd Novel compounds
CA2532102A1 (fr) * 2003-07-15 2005-02-03 Merck & Co., Inc. Modulateurs benzylamides de cyclopentyle heterocycliques a 7 et 8 elements, utiles pour moduler l'activite des recepteurs de chimiokines

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007024183A1 *

Also Published As

Publication number Publication date
MX2008002320A (es) 2008-03-14
KR20080038178A (ko) 2008-05-02
RU2008108176A (ru) 2009-10-10
BRPI0615064A2 (pt) 2011-05-03
CA2620281A1 (fr) 2007-03-01
WO2007024183A1 (fr) 2007-03-01
IL189182A0 (en) 2008-08-07
US20090298875A1 (en) 2009-12-03
AU2006282122A1 (en) 2007-03-01
NO20081483L (no) 2008-05-16
JP2009506029A (ja) 2009-02-12

Similar Documents

Publication Publication Date Title
US11090294B2 (en) Combinations of a muscarinic receptor antagonist and a beta-2 adrenoreceptor agonist
AU2009202925B2 (en) A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (COPD) and asthma
JP5208473B2 (ja) アゼラスチンと抗コリン薬を含有する医薬組成物
EP3578169A1 (fr) Préparations pharmaceutiques comprenant 4-{(1r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]éthoxy}hexyl)amino]-1-hydroxyéthyl}-2-(hydroxyméthyl)-phénol
US20090298875A1 (en) A Combination of Compounds, Which Can be Used in the Treatment of Respiratory Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma
US20110124613A1 (en) Novel Combination of Compounds to be Used in the Treatment of Airway Diseases, Especially Chronic Obstructive Pulmonary Disease (COPD) and Asthma
EP2717867A1 (fr) Composition pour inhalateur de poudre sèche comprenant de l'uméclidinium
EP1427414A1 (fr) Compositions a inhaler comprenant des 5,6-dihydro-9h-pyrazolo (3,4-c)-1,2,4-triazolo(4,3-alpha)pyridines tricycliques
WO2010097114A1 (fr) Nouvelle combinaison d'agents thérapeutiques
JP2006506402A (ja) 四級アンモニウム化合物およびその抗ムスカリン薬としての使用
WO2007008157A1 (fr) Nouvelle combinaison 2
JP2021536467A (ja) 喘息またはパーキンソン病の処置のための方法および組成物
CN101296701A (zh) 用于治疗呼吸系统疾病,尤其是慢性阻塞性肺病(copd)和哮喘的化合物的组合
CN101296698A (zh) 用于治疗呼吸系统疾病，尤其是慢性阻塞性肺病（copd）和哮喘的化合物的组合
JPWO2004087150A1 (ja) 医薬組成物

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080326

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: HR

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1116096

Country of ref document: HK

17Q First examination report despatched

Effective date: 20090715

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20091126

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1116096

Country of ref document: HK